Molecular Analysis in a Glioblastoma Cohort—Results of a Prospective Analysis

The prognostic role of epidermal growth factor receptor variant III (EGFRvIII), a constitutively\r\nactivated oncogenic receptor, in glioblastoma is controversial. We performed a prospective\r\nstudy enrolling 355 patients operated on for de novo glioblastoma at a large academic center.\r\nThe molecular profile, including EGFRvIII status, MGMT promoter methylation, and VEGF expression,\r\nwas assessed. Standard parameters (age, clinical status and extent of surgical resection) were\r\nconfirmed to hold prognostic value. MGMT promoter methylation portended a slightly improved\r\nsurvival. In the whole series, confirming previous results, EGFRvIII was not associated with worsened\r\nprognosis. Interestingly, female sex was associated with a better outcome. Such findings are of\r\ninterest for the design of future trials.